EP4106757
Aðferðir sem snúa að dauffrumu-elastasa-hindra alvelestat til meðhöndlunar á öndunarfærasjúkdómi sem er miðlað af alfa-1 andtrypsín-skorti
Status:
EP einkaleyfi í gildi á ÍslandiEP appl. date:
16.3.2021EP published:
23.8.2023EP application number:
21714345.2
EP translation filed:
23.10.2023Grant published:
15.11.2023EPO information:
European Patent Register
Max expiry date:
15.3.2041Expiry date:
15.3.2027Next due date:
31.3.2027
Title in English:
METHODS INVOLVING NEUTROPHIL ELASTASE INHIBITOR ALVELESTAT FOR TREATING RESPIRATORY DISEASE MEDIATED BY ALPHA-1 ANTITRYPSIN DEFICIENCYLanguage of the patent:
English
Timeline
Today
16.3.2021EP application
23.8.2023EP Publication
23.10.2023Translation submitted
15.11.2023Registration published
15.3.2027Expires
Owner
Name:
Mereo Biopharma 4 LimitedAddress:
1 Cavendish Place, London Greater London W1G 0QF, GB
Inventor
Name:
PARKIN, JacquelineAddress:
London W1G 0QF, GB
Agent
Name:
Árnason Faktor ehf.Address:
Guðríðarstíg 2-4, 113, Reykjavík,
Priority
Number:
202005519Date:
16.4.2020Country:
GB
Number:
202005520Date:
16.4.2020Country:
GB
Number:
202062706195 PDate:
4.8.2020Country:
US
Classification
Categories:
A61K 31/444, A61K 45/06, A61P 11/00, A61P 29/00
Annual fees
Number
Paid
Expires
Payer
Number: 4
Paid: 14.2.2024
Expires: 15.3.2025
Payer: Árnason Faktor ehf.
Number: 5
Paid: 11.2.2025
Expires: 15.3.2026
Payer: Árnason Faktor ehf.
Number: 6
Paid: 9.3.2026
Expires: 15.3.2027
Payer: Árnason Faktor ehf.